Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Firma predictiva de la respuesta a benralizumab (BENRAPRED)

10 de noviembre de 2026 actualizado por: Nantes University Hospital

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.

This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

85

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Aix-en-Provence, Francia
        • Centre hospitalier Intercommunal Aix-en-Provence
      • Angers, Francia
        • CHU Angers
      • Bordeaux, Francia
        • CHU Bordeaux
      • Brest, Francia
        • CHRU Brest
      • Dijon, Francia
        • CHU Dijon
      • Grenoble, Francia
        • CHU Grenoble
      • Le Kremlin-Bicêtre, Francia
        • Hôpital Bicêtre - AP-HP
      • Le Mans, Francia
        • CH Mans
      • Lille, Francia
        • CHU Lille
      • Lyon, Francia
        • Hospices Civils de Lyon
      • Marseille, Francia
        • Assistance Publique des Hôpitaux de Marseille
      • Montpellier, Francia
        • CHU Montpellier
      • Nantes, Francia
        • CHU Nantes
      • Orléans, Francia
        • CHR Orléans
      • Paris, Francia
        • Hôpital Bichat - AP-HP
      • Rouen, Francia
        • CHU Rouen
      • Strasbourg, Francia
        • CHU Strasbourg
      • Suresnes, Francia
        • Hôpital FOCH
      • Toulouse, Francia
        • CHU Toulouse
      • Villeurbanne, Francia
        • Médipôle Hôpital Mutualiste de Villeurbanne

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients between 18 and 75 years old.

  • Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:

    • asthma requiring high doses of ICS (>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and/or systemic corticosteroids to be controlled over one year,
    • and/or uncontrolled asthma despite the later medications,
    • and/or a controlled asthma worsening after decreasing medications,
  • Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter

  • ACQ-7 score ≥ 1,5 at M0.

  • ≥ 3 exacerbations in the 12 months prior to screening visit M-1.

  • Eosinophil blood count ≥ 0,3 G/L at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G/L and < 0,3 G/L, an eosinophilic phenotype defined by at least 1 of the following criteria will be required:

    • Fractional Exhaled Nitric Oxide (FeNO) > 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit.
    • Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit.
  • Patients who provide written informed consent prior to participation in the study

Exclusion Criteria:

  • Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/COPD overlap syndrome).
  • Non-adherent patients to inhaled treatment (ICS + LABA).
  • Active smokers or former smokers exceeding 20 packs year.
  • Exacerbation at inclusion visit M0.
  • Active malignancy or malignancy in remission over less than 5 years.
  • Active parasitic infection or parasitic infection in the past 24 weeks.
  • Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20)
  • Patients requiring other immunosuppressive and immunomodulator drugs
  • Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma
  • Patients requiring other biotherapy than Benralizumab that affects the immune system
  • SARS-COV2 infection
  • Pregnancy, lactation, or patients with childbearing potential refusing efficient contraceptive method.
  • Patients under psychiatric condition altering their comprehension and their ability to give informed consent.
  • Patients already enrolled in a clinical interventional research.
  • Patients not affiliated to a health insurance plan
  • Patients under guardianship, curators or safeguard of justice

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: BENRALIZUMAB

Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

Otros nombres:
  • Transcriptómico

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Predictive value of early blood gene expression signature of Benralizumab
Periodo de tiempo: 12 months

To establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. We will evaluate an early blood gene expression signature of Benralizumab response through a clinically relevant reduction of the number of exacerbations at month 12 (M12).

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Molecular signature predictive of stabilization
Periodo de tiempo: 12 months

To establish at M0 (baseline) a molecular signature predictive of stabilization in severe asthmatic patients treated by Benralizumab. At M0 a composite blood molecular signature predictive of reduction of the exacerbation rate at M12 in severe asthmatic patients treated by Benralizumab will be assessed. The definition of stable class of patients (low category) is used as a target for the prediction. The methods used for the primary objective are applied to secondary objective using similar input data on a different 3-class prediction target.

12 months
The stability of the signature over time
Periodo de tiempo: 0 month, 3 months, 6 months and 9 months

To evaluate the stability of the signature over time (from early at M0, M3, to late prediction at M6 and M9) considering patient trajectories. The significance of center and the relevance of time dependent modelling will be evaluated using generalised mixed models on independently established molecular response signature. It is expected a robust and reproducible gene expression to assess the inter and intra-individual trajectories of the signature over time and across centers (from early at M0 and M3, to late prediction at M6 and M9).

0 month, 3 months, 6 months and 9 months
The association of gene expression patterns
Periodo de tiempo: 12 months

To evaluate the association of gene expression patterns with both objective and subjective improvement. Correlations network between blood gene expression of Benralizumab significant response will be assessed thanks to weighted gene correlation network analysis (gene co-expression network analysis (WGCNA)) with an expected increase in forced expiratory volume at one second (FEV1) + Asthma Quality of Life Questionnaire (AQLQ) + peak-flow values and expected decrease of Asthma Control Questionnaire-7 items (ACQ-7), -6 items (ACQ-6) scores.

12 months
Association of gene expression patterns and clinical characteristics
Periodo de tiempo: 0 months

To evaluate association of gene expression patterns at M0 (baseline) and clinical characteristics of frequent exacerbations. Correlations network between blood gene expression at M0 and clinical characteristics of frequent exacerbations will be assessed thanks to WGCNA.

0 months
Stratification value of gene expression in severe asthma
Periodo de tiempo: 12 months

To assess the stratification value of gene expression in severe asthma and its correlation with clinical subgroups and clinically meaningful variables such as number of exacerbations. Correlation network between stratification value of gene expressions in severe asthma and its correlation with clinical subgroups will be assessed thanks to WGCNA. This analysis is based on pairwise correlations between genetic variables and clinical variables underlying the amount of overall variance captured by high dimensional gene expression datasets.

12 months
Scenario-based cost-utility analysis
Periodo de tiempo: 12 months

To conduct a scenario-based cost-utility analysis.Concerning cost-utility analysis, two strategies of treatment with Benralizumab will be compared: the first one will consider a strategy not using an early blood gene expression signature of Benralizumab response and the second will consider a simulated strategy using an early blood gene expression signature of Benralizumab response.

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de octubre de 2021

Finalización primaria (Actual)

19 de agosto de 2026

Finalización del estudio (Actual)

19 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

21 de septiembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

21 de septiembre de 2020

Publicado por primera vez (Actual)

25 de septiembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir